 |
|
Erectile dysfunction drugs allowed more chemotherapy to reach brain tumors in laboratory study
July 29, 2008In a study using laboratory animals, researchers found that medications commonly prescribed for erectile dysfunction opened a mechanism called the blood-brain tumor barrier and increased delivery of cancer-fighting drugs to malignant brain tumors.
The experiments were conducted at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute and published in Brain Research.
Viagra (sildenafil) and Levitra (vardenafil) are known as PDE5 inhibitors because they block an enzyme, phosphodiesterase5, which interrupts a series of biochemical events that cause the decreased blood flow of erectile dysfunction. This laboratory rat study, published online ahead of print in the journal, found that similar biochemical interactions in the small vessels of the brain play a major role in the blood-brain tumor barrier, which impedes delivery of anti-tumor drugs into brain tumors. PDE5 inhibitors were found to open the barrier and increase drug transport in this early animal study.
Although the normal blood-brain barrier, which regulates access to the brain from the bloodstream, shares many characteristics with the blood-brain tumor barrier, the signaling mechanism blocked by PDE5 inhibitors is unique to the blood-brain tumor barrier. This allows the PDE5 inhibitors to selectively increase drug transport to malignant brain tumors without affecting normal brain tissue.
According to the researchers, these findings may have significant implications in improving drug delivery to brain tumors in patients.
"This is the first study to show that oral administration of PDE5 inhibitors increases the rate of transport of compounds across the blood-brain tumor barrier and improves the effectiveness of the anti-tumor drug adriamycin in the treatment of brain tumors in a rat model. We chose adriamycin for this study because it is one of the most effective drugs against brain tumor cell lines in the laboratory but it has very little effect in animals and humans because it is unable to cross the blood-brain tumor barrier. The combination of vardenafil and adriamycin resulted in longer survival and smaller tumor size," said neurosurgeon Keith L. Black, M.D., chairman of the Department of Neurosurgery at Cedars-Sinai Medical Center and director of the Maxine Dunitz Neurosurgical Institute.
Black, the article's first and corresponding author, has been recognized for his earlier groundbreaking work to break through the blood-brain tumor barrier with natural and synthetic bradykinin, a peptide that temporarily opens the barrier and increases anti-cancer drug delivery into certain tumors by more than 1,000 percent. In 2000, he received the Javits Neuroscience Investigator Award from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, for his blood-brain barrier research.
In the current studies, the blood-brain tumor barrier-opening effects of PDE5 lasted considerably longer than those of bradykinin and allowed greater transport across the barrier into tumor tissues. Because vardenafil was found to be more effective than sildenafil in increasing blood-brain tumor barrier permeability and transport, vardenafil was used in a survival study of 29 tumor-bearing rats. Those treated with saline (control) survived 32 days on average while those treated with vardenafil alone survived about 35 days and those treated with adriamycin alone survived about 42 days. When vardenafil was combined with adriamycin, rats survived an average 53 days.
Although the researchers exposed the laboratory animals to doses of sildenafil and vardenafil that are comparable to the dose range approved for erectile dysfunction in humans, there were no detectable side effects in the rats, and neither drug increased transport of tracers into normal brain tissue.
Cedars-Sinai Medical Center
Although the normal blood-brain barrier, which regulates access to the brain from the bloodstream, shares many characteristics with the blood-brain tumor barrier, the signaling mechanism blocked by PDE5 inhibitors is unique to the blood-brain tumor barrier. This allows the PDE5 inhibitors to selectively increase drug transport to malignant brain tumors without affecting normal brain tissue.
According to the researchers, these findings may have significant implications in improving drug delivery to brain tumors in patients.
"This is the first study to show that oral administration of PDE5 inhibitors increases the rate of transport of compounds across the blood-brain tumor barrier and improves the effectiveness of the anti-tumor drug adriamycin in the treatment of brain tumors in a rat model. We chose adriamycin for this study because it is one of the most effective drugs against brain tumor cell lines in the laboratory but it has very little effect in animals and humans because it is unable to cross the blood-brain tumor barrier. The combination of vardenafil and adriamycin resulted in longer survival and smaller tumor size," said neurosurgeon Keith L. Black, M.D., chairman of the Department of Neurosurgery at Cedars-Sinai Medical Center and director of the Maxine Dunitz Neurosurgical Institute.
Black, the article's first and corresponding author, has been recognized for his earlier groundbreaking work to break through the blood-brain tumor barrier with natural and synthetic bradykinin, a peptide that temporarily opens the barrier and increases anti-cancer drug delivery into certain tumors by more than 1,000 percent. In 2000, he received the Javits Neuroscience Investigator Award from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, for his blood-brain barrier research.
In the current studies, the blood-brain tumor barrier-opening effects of PDE5 lasted considerably longer than those of bradykinin and allowed greater transport across the barrier into tumor tissues. Because vardenafil was found to be more effective than sildenafil in increasing blood-brain tumor barrier permeability and transport, vardenafil was used in a survival study of 29 tumor-bearing rats. Those treated with saline (control) survived 32 days on average while those treated with vardenafil alone survived about 35 days and those treated with adriamycin alone survived about 42 days. When vardenafil was combined with adriamycin, rats survived an average 53 days.
Although the researchers exposed the laboratory animals to doses of sildenafil and vardenafil that are comparable to the dose range approved for erectile dysfunction in humans, there were no detectable side effects in the rats, and neither drug increased transport of tracers into normal brain tissue.
Cedars-Sinai Medical Center
Brain Tumor Current Events and Brain Tumor News RSSNew imaging technique tracks cancer-killing cells over prolonged period
Coaxing a patient's own cells to hunt down and tackle infected or diseased cells is a promising therapeutic approach for many disorders.
Mechanism in cells that generate malignant brain tumors may offer target for gene therapy
Researchers at Cedars-Sinai Medical Center's Maxine Dunitz Neurosurgical Institute who first isolated cancer stem cells in adult brain tumors in 2004 have now identified a molecular mechanism that is involved in the development of these cells from which malignant brain tumors may originate.
Pediatric study finds alternatives for radiation of low-grade brain tumors
A multi-institutional study led by researchers at The University of Texas M. D. Anderson Cancer Center has found that using chemotherapy alone and delaying or avoiding cranial radiation altogether can be effective in treating pediatric patients with unresectable or progressive low-grade glioma.
New approach to gene therapy may shrink brain tumors, prevent their spread
Massachusetts General Hospital (MGH) researchers are investigating a new approach to gene therapy for brain tumors - delivering a cancer-fighting gene to normal brain tissue around the tumor to keep it from spreading.
Family history of brain tumors linked to increased risk of brain cancer
People with a family history of cancerous brain tumors appear to be at higher risk of developing the same kind of tumors compared to people with no such family history.
Barrow researchers identify a new approach to detect the early progression of brain tumors
Researchers at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center recently participated in a pilot study with the Montreal Neurological Institute that suggests a certain type of MRI scanning can detect when a patient is failing brain tumor treatment before symptoms appear.
Childhood brain tumor traced to normal stem cells gone bad
An aggressive childhood brain tumor known as medulloblastoma originates in normal brain "stem" cells that turn malignant when acted on by a known mutant, cancer-causing oncogene, say researchers from Dana-Farber Cancer Institute and the University of California, San Francisco (UCSF).
Certain anticancer agents could be harmful to patients with heart disease
A set of promising new anticancer agents could have unforeseen risks in individuals with heart disease, suggests research at Washington University School of Medicine in St. Louis.
St. Jude finds young age may give survival advantage to children with certain brain tumors
St. Jude Children's Research Hospital investigators have shown that children under 3 years old who have a brain tumor called diffuse pontine glioma (DPG) appear to have a better outcome than older children with the same cancer.
Brown Chemists Create Cancer-Detecting Nanoparticles
A team led by a Brown University chemist has created the smallest iron oxide nanoparticles to date for cancer detection by magnetic resonance imaging (MRI). The magnetic nanoparticles operate like tiny guided missiles, seeking and attaching themselves to malignant tumor cells. Once they bind, the particles emit stronger signals that MRI scans can detect.
More Brain Tumor Current Events and Brain Tumor News Articles
 | Living with a Brain Tumor: Dr. Peter Black's Guide to Taking Control of Your Treatment by Peter Black Each year, 100,000 people in the United States are diagnosed with a brain tumor. With his new book, Dr. Peter Black fills a gap in the lay readership, providing an accessible medical resource for adult patients and their families. Dr. Black, who has operated on more than 3,000 patients with brain tumors, is uniquely qualified to discuss both clinical treatment of and research into brain tumors.... |
 | Brain Tumors: Finding the Ark. Meeting the Challenges of Treatment Choices, Side Effects, Childrens Issues, Healthcare Costs and Long Term Survival by Paul M. Zeltzer In this sequel to Brain Tumors: Leaving the Garden of Eden, Dr. Paul continues to guide you through the brain tumor minefield so you have the best chances for quality survival. Here are the key answers to questions about medications, side effects and late effects of treatment, insurance, Medicare & HMOs, clinical trials, heredity, brain tumors in children, Complementary and Alternative... |
 | Brain Tumors: Leaving the Garden of Eden--A Survival Guide to Diagnosis, Learning the Basics, Getting Organized, and Finding Your Medical Team by Paul M. Zeltzer A guidebook for the 150,000+ people/ year and families affected by brain tumors. This book will help you learn the basics about diagnosis, getting organized and finding your medical team. Included are chapters on all major types of brain tumors & metastases, glossary, medications, using the Internet to search for information, and getting a second opinion. "Brain Tumors:Leaving the Garden of... |
 | Damn The Statistics, I Have a Life to Live!: Coping with a Brain Tumor My Personal Story by H. Charles Wolf |
 | Curveball: When Life Throws You a Brain Tumor by Liz Holzemer Life seemed idyllic for thirty-two-year-old Liz Holzemer. Wife of Major League Baseball pitcher Mark Holzemer, Liz was enjoying a successful career as a journalist when an MRI revealed a baseball-size brain tumor she soon found out was called meningioma. Told with clarity and unwavering humor, this book is an inspirational and informative account of one woman's battle for her life. It shows... |
 | Childhood Brain & Spinal Cord Tumors: A Guide for Families, Friends & Caregivers by Tania Shiminski-Maher, Patsy McGuire Cullen, Maria Sansalone Childhood Brain & Spinal Cord Tumors, the most complete parent guide available, includes detailed and precise medical information about both benign and malignant brain and spinal cord tumors that strike children and adolescents. In addition, it offers day-to-day practical advice on how to cope with procedures, hospitalization, family and friends, school, social and financial issues,... |
 | Guerilla Guide to Brain Tumors: Shameless Dirty Tricks to beat the system and STAY ALIVE! by Skip Goebel In an unprecedented format, the Guerilla Guide to Brain Tumors is written in a format that combines the layout of the For Dummies series with a drill-sargent's attitude. (the back page says it all) This is a book of War Nothing warm and fuzzy or socially acceptable here and nothing about "Dying with Dignity". Just what it takes to win. And win... |
 | Searching for Normal, My Life with a Brain Tumor by Mikki Baker This is a simple and true story of a young nurse, wife and mother of three, leading a typical American middle-class life, until one day in April 2003. It is a deeply personal and detailed account from Mikki Baker, of how a grand mal seizure on Easter Monday led to the discovery of a large brain tumor, and sent her life and the lives of her family into initial chaos, and how it forever changed the... |
 | Navigating Through a Strange Land: 2nd Edition: A Book for Brain Tumor Patients and Their Families, by Tricia Ann Roloff Includes practical advice along with the moving personal stories of brain tumor patients, their family members, and their professional... |
 | Brain Tumors (Fast Facts) by Lauren E., M.D. Abrey, Warren P. Mason Memorial Sloan-Kettering Cancer Center, New York, NY. Pocket-size text describes the features, imaging modalities, and treatment options for brain tumors. Discusses the various tumor types in detail, providing clear information about preferred treatment strategies. For primary care physicians. Attractive color layout with black and white illustrations.... |
| © 2008 BrightSurf.com |